Keyword: Fresenius Kabi

Fresenius Kabi missed an opportunity to quickly bulk up in sterile manufacturing when its $5 billion deal to buy Akorn imploded last year.

Just weeks after being hit with an FDA letter for its Illinois manufacturing operations, the FDA tagged a different Akorn plant with a Form 483.

Following a handful of deals for other biosimilar drugmakers, Pfizer decided to settle its Humira patent fight with AbbVie.

Fresenius recalls 163 lots of sodium chloride, the CEO of MHRA is leaving, plus other manufacturing news.

The FDA issued a 22-page, 11-observation Form 483 to Akorn’s Parsippany, New Jersey, plant following a five-week inspection.

In a Humira patent deal with AbbVie, Fresenius Kabi will have to pay undisclosed royalties and can launch its biosim in Europe upon approval.

Fresenius continues to hammer Akorn with fraud allegations as the company tries to extract itself from a $4.3 billion buyout of the injectables maker.

Fresenius’ $4.3 billion buyout of generics maker Akorn is in jeopardy as they investigate allegations that Akorn violated FDA drug development standards.

The FDA has decided that Fresenius Kabi’s retrieval of more than 200,000 syringes rises to the level of a Class I recall.

With plans for a major expansion of its site North Carolina, Fresenius Kabi's investments aimed mainly at the U.S. generics market now top $5 billion.